Sandoz launches Kerydin topical solution

PRINCETON, N.J. — Sandoz announced the launch of Kerydin (tavaborole) topical solution, 5% in the United States. Kerydin is the first oxaborole antifungal for the topical treatment of onychomycosis of the toenails due to trichophyton rubrum or trichophyton mentagrophytes, the company stated. 

 

"Kerydin is an important product addition in PharmaDerm’s portfolio and helps to reinforce our leadership in the topical dermatology specialty market,” said Peter Goldschmidt, president of Sandoz.

 

The drug was developed by Anacor Pharmaceuticals. Sandoz earlier this year announced an agreement with the company to obtain exclusive rights to commercialize Kerydin in the United States.